|
1876
|
|
Lilly is founded as sole proprietorship in
Indianapolis, Indiana by Colonel Eli Lilly.
|
|
1922
|
|
Lilly researchers collaborated with Frederick Banting and Charles Best of the University of Toronto to isolate and purify insulin, for the treatment of diabetes, at that time a fatal disease with no effective treatment. This resulted in Lilly introducing the world’s first insulin product in 1923.
|
|
1928
|
|
Lilly develops the first effective treatment for pernicious anaemia; the researchers share a Nobel prize.
|
|
1934
|
|
Lilly first overseas office was opened in London. From this moment on, the UK would become an important part of the overall Company’s strategy.
|
|
1939
|
|
Lilly´s first overseas manufacturing plant is opened at Basingstoke in the UK.
|
|
1943
|
|
Full scale production of Penicillin begins. This marked the beginning of many pioneering efforts in the field of infectious diseases.
|
|
1958
|
|
Lilly introduces vancomycin, still our last line of defence against serious hospital infections.
|
|
1964
|
|
The first cephalosporin product, KeflinTM, is launched.
|
|
1967
|
|
Lilly sets up its first research facility outside the US at Erl Wood Manor in the UK.
|
|
1974
|
|
Lilly receives the Queens Award for Trade in the UK
|
|
1982
|
|
Lilly introduces HumulinTM, the first human insulin product, also the world’s first biotechnology product using recombinant DNA technology.
|
|
1986
|
|
Launched a new class of medicines – selective serotonin reuptake inhibitors – for the treatment of clinical depression, which has been used by more than 49 million people world-wide
|
|
1990
|
|
Lilly becomes the first pharmaceutical company to buy a supercomputer for use in simulating complex molecules in drug development.
|
|
1995
|
|
Lilly launches its anti-clotting drug ReoProTM and HumalogTM, the first rapid-acting insulin analogue.
|
|
1996
|
|
Lilly introduces GemzarTM, the first new treatment for pancreatic cancer in decades, and Zyprexa for the treatment of schizophrenia. Lilly receives the Queen’s Award for Trade for the second time.
|
|
1998
|
|
Lilly introduces EvistaTM, its product for the prevention and treatment of post-menopausal osteoporosis.
|
|
1999
|
|
Together with Takeda Chemical Industries, Ltd., Lilly launches ActosTM, an oral diabetes agent.
|
|
2000
|
|
Lilly receives the Queen´s Award for Innovation and the Prix Galien for the discovery of ZyprexaTM.
|
|
2001
|
|
Lilly receives the Queen´s Award for Export for the third time
|
|
2002
|
|
Lilly launches XigrisTM in the UK, the worlds first treatment specifically indicated for severe sepsis
|
|
2003
|
|
Lilly launched ForsteoTM for severe osteoporosis in post menopausal women and CialisTM for erectile dysfunction
|
|
2004
|
|
Lilly launched three new treatments: StratteraTM, the first non-stimulant for the treatment of attention-deficit hyperactivity disorder in children and adolescents; YentreveTM, the first treatment for moderate and severe stress urinary incontinence in women; and AlimtaTM the first treatment for mesothelioma, a cancer caused by exposure to asbestos.
|
|
2005
|
|
Lilly launched CymbaltaTM for depression
|
|
2007
|
|
Lilly launched BYETTA®, the first in a new class of medicines known as incretin mimetics and used in the treatment of type 2 diabetes (in conjunction with oral antidiabetic
therapy)
|
About
